Sharing the Wealth

From research results to electronic health records, biomedical data are becoming increasingly accessible. How can scientists best capitalize on the information deluge?

Written byJef Akst
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

© EXDEZ/ISTOCKPHOTO.COMIn February 2013, the US Office of Science and Technology Policy issued a memorandum to federal departments and agencies directing those that contribute more than $100 million annually to research to develop a plan for increasing public access to study findings. Data generated by federally funded research should be made “publicly accessible to search, retrieve, and analyze,” the letter read. The Fair Access to Science and Technology Research (FASTR) Act, introduced to Congress the same month, aims to codify the mandate. The European Commission has similarly recommended, and announced that it would soon require, that its member states pass policies to ensure the digital accessibility of research data supported by public funds.

While these initiatives are being met with some resistance—the Frontiers in Innovation, Research, Science and Technology (FIRST) Act, for example, which would limit public access to federally funded research results, is also currently making its way through the US Congress—there is a clear push for widespread sharing of research findings. This attitude has driven the creation of more than 600 data repositories that enable sharing among the science community and often the public, with more than 200 of those focusing on data from the life sciences. Many universities and research institutions are launching their own repositories, while clinical data from health-care centers, Big Pharma, and even patients themselves are also being made accessible.

“It’s becoming clearer and clearer how important it is to share,” says ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

    View Full Profile

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies